<DOC>
	<DOCNO>NCT02793466</DOCNO>
	<brief_summary>This clinical trial first clinical trial study Durvalumab , checkpoint inhibitor stimulate patient 's immune system act cancer cell child adolescent . This trial ass safety tolerability Durvalumab child adolescent also study Durvalumab process body .</brief_summary>
	<brief_title>Durvalumab Pediatric Adolescent Patients</brief_title>
	<detailed_description>This trial ass safety tolerability Durvalumab child adolescent also study Durvalumab process body .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Age : Patients must &gt; 12 month &lt; 18 year age time study enrollment . 2 . Diagnosis : Patient must disease either refractory frontline treatment relapse . Patient must histologic verification solid tumor ( include lymphoma CNS tumor ) time original diagnosis relapse follow exception : 1 . Patients germ cell tumor ( CNS nonCNS ) elevate tumor marker ( e.g . αfetoprotein , βhuman chorionic gonadotropin , inhibin A/B ) radiographic evidence disease . 2 . Patients diffuse intrinsic pontine glioma ( DIPG ) diagnose radiographic study . 3 . Disease Status : Patients must either measurable evaluable disease accurately assess baseline computerize tomography ( CT ) magnetic resonance imaging ( MRI ) suitable repeat assessment follow exception : . Patients third relapse osteosarcoma measurable disease surgical resection eligible study . 4 . Therapeutic Options : Patient 's current disease state must one know curative therapy . 5 . Performance Level : Karnofsky ≥ 50 patient &gt; 16 year age Lansky ≥ 50 patient ≤ 16 year age . Patients unable walk paralysis , actively sit wheelchair , consider ambulatory purpose assess performance score . See Appendix I score guideline . 6 . Organ Function Requirements : Adequate organ bone marrow function define : 1 . Absolute neutrophil count ≥ 750/mm3 2 . Platelets ≥ 75,000/mm3 . Patients must transfusion independent receive platelet transfusion within 5 day enrollment . 3 . Hemoglobin ≥8.0 g/dL . Patients may receive PRBC transfusion . 4 . Adequate renal function define : Creatinine clearance radioisotope GFR &gt; 70ml/min/m 2 5 . Total serum bilirubin ( conjugated plus unconjugated ) ≤1.5 x upper limit normal ( ULN ) age . For patient Hepatocellular Carcinoma ( HCC ) patient documented/suspected Gilbert 's disease , bilirubin ≤3x ULN . 6 . In patient liver metastasis : AST ALT ≤2.5 x ULN 7 . In patient HCC liver metastasis : AST ALT ≤5 x ULN 8 . Adequate cardiac function indicate shorten fraction &gt; 28 % echocardiogram ejection fraction ≥ 55 % radionuclide angiogram . 7 . Informed Consent : Provision sign date write informed consent ( parent/legal guardian patient &lt; 18 year age ) assent ( patient age &gt; 7 year ) prior study specific procedure , sample analysis , include screen evaluation . 8 . Female patient must either nonreproductive potential must negative serum pregnancy test upon study entry . 9 . Subject willing able comply protocol duration study include undergoing treatment schedule visit well follow examination . 1 . Prior therapy : 1 . Nitrosourea mitomycin C within 6 week first dose study treatment . 2 . Any investigational agent study drug previous clinical study within 28 day first dose study treatment . Patient may enrol nontherapeutic study . 3 . Hematopoietic growth factor : Within 14 day last dose long act growth factor ( e.g . Neulasta ) within 7 day receive short act growth factor . This apply erythropoetin . 4 . Monoclonal antibody : Less 3 halflives 28 day ( whichever shorter ) last dose monoclonal antibody , without resolution know toxicity antibody . 5 . Any chemotherapy , immunotherapy anticancer agent within 4 week first dose study treatment . For agent know adverse event occur beyond 3 week administration administration , period must extend beyond time adverse event know occur . 6 . Any previous systemic exposure PD1 PDL1 inhibitor , include Durvalumab . 7 . Major surgery ( exclude placement vascular access needle biopsy ) within 2 week first dose study treatment . 8 . Radiotherapy within two week local palliative XRT within 6 week craniospinal XRT ≥ 50 % radiation pelvis . 9 . Current prior use immunosuppressive medication within 28 day first dose Durvalumab , exception intranasal inhaled corticosteroid systemic corticosteroid physiological dos , exceed 10 mg/day prednisone , equivalent corticosteroid . 10 . Any prior allogeneic BMT/HSCT . 11 . Autologous BMT/HSCT within 90 day . 2 . All prior acute toxicity medical therapy radiation therapy resolve meet baseline inclusion criterion regard organ function requirement . All prior acute toxicity part baseline organ function requirement must improve ≤ Grade 1 define Section 5.1.1 use CTCAE Criteria Version 4.03 . 3 . Any following cardiac criterion : 1 . Mean resting correct QT interval ( QTc ) &gt; 470 msec obtain least 2 electrocardiogram ( ECGs ) . 2 . Any clinically important abnormality rhythm , conduction morphology rest ECG ( e.g. , complete leave bundle branch block , third degree heart block ) 3 . Any factor increase risk QTc prolongation risk arrhythmic event heart failure , congenital long QT syndrome , family history long QT syndrome unexplained sudden death 40 year age concomitant medication know prolong QT interval . 4 . Judgment investigator patient participate study patient unlikely comply study procedure , restriction requirement 5 . Any prior Grade ≥3 immunerelated adverse event ( irAE ) receive previous immunotherapy agent , unresolved irAE &gt; Grade 1 . 6 . Active prior document autoimmune disease within past 2 year . NOTE : Patients vitiligo , Grave 's disease , psoriasis require systemic treatment ( within past 2 year ) exclude . Patients hypothyroidism result irradiation thyroidectomy also exclude . 7 . Active prior document inflammatory bowel disease ( e.g. , Crohn 's disease , ulcerative colitis ) . 8 . History primary immunodeficiency . 9 . Any underlying interstitial lung disease . 10 . Brain metastasis spinal cord compression unless asymptomatic , treat stable least 1 month prior entry study . 11 . Ongoing expect need systemic corticosteroid ≥10mg/day . 12 . Known history orf previous clinical diagnosis tuberculosis . 13 . Receipt live attenuate vaccination within 30 day prior receive study treatment . Inactivated virus , influenza vaccine , permit 14 . History another primary malignancy within 5 year prior start study treatment , except adequately treat basal squamous cell carcinoma skin cancer cervix situ disease study . 15 . Pregnancy BreastFeeding : Pregnant patient ineligible study due unknown teratogenic effect agent . Pregnancy test must obtain female childbearing potential prior enrollment . 16 . Postmenarchal females male sexually active woman childbearing potential employing/willing employ effective method birth control . 17 . Clinically Significant Unrelated Systemic Illness : Patients serious infection significant pulmonary , hepatic , renal , endorgan dysfunction judgment Principal CoInvestigators would compromise patient 's ability tolerate prescribe chemotherapy likely interfere study procedure result eligible . 18 . Patient HIV , Hepatitis B , Hepatitis C define follow serology result : 1 . Positive human immunodeficiency virus ( HIV ) antibody . 2 . Positive hepatitis B surface antigen ( HBsAg ) positive hepatitis B core ( HBc ) antibody undetectable hepatitis B ( HBV ) deoxyribonucleic acid ( DNA ) quantitative polymerase chain reaction ( PCR ) test . 3 . Positive hepatitis C ( HCV ) antibody positive HCV ribonucleic acid ( RNA ) quantitative PCR . 19 . Any condition , opinion investigator , would interfere evaluation study treatment interpretation patient safety study result . 20 . History hypersensitivity Durvalumab excipient .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Durvalumab</keyword>
	<keyword>solid tumor</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Check Point Inhibitor</keyword>
	<keyword>pediatrics</keyword>
	<keyword>child</keyword>
</DOC>